Advances in Applications to Drive Growth of Cell/Tissue Culture Supplies Market, According to New Report by Global Industry Analysts, Inc.

GIA announces the release of a comprehensive global report on Cell/Tissue Culture Supplies markets. Global market for Cell/Tissue Culture Supplies is projected to reach US$5.6 billion by 2018, driven by advances in biotechnology and life science research coupled with broader range of application areas. Going forward, the market for Cell/Tissue Culture Supplies is expected to grow at an impressive pace, fueled by heightened interest in biopharmaceutical therapeutics, human and veterinary vaccine applications, and growing success of industrial biopharmaceuticals.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Cell/Tissue Culture Supplies: A Global Strategic Business Report

San Jose, California (PRWEB) October 23, 2012

Follow us on LinkedIn – The evolution of cell culture technologies witnessed the successful incorporation of a number of segments such as cell biology, genetic engineering, protein chemistry, genomics and chemical engineering into the cell culture field, thus serving to enrich the cell/tissue culture domain. Influencing factors such as enhanced competition, patent expiries, R&D spends, novel technologies, and the allure of a global trading zone are predicted to lend momentum to the cell/tissue culture supplies market. Over time, with country of origin having become a major quality consideration for ingredients and media, most biomanufacturers are now sourcing closer to home. With quality auditing being traced back to the suppliers of ingredients and equipment used to make media components and not just the media, media ingredient suppliers are expected to maintain manufacturing systems and utilize ingredients that are verified and authenticated according to customer’s specifications.

Growing awareness about applications of biotherapeutics is driving the market for products from cell cultivation. Cells play a major role in the development of biopharma drugs such as therapeutic enzymes, monoclonal antibodies (mABs), interferons, vaccines, thrombolytics, blood factors and hormones for treating life-threatening diseases. Increasing number of protein based drugs in final phases of testing for therapeutic uses also denotes the rising market for media. Mammalian cell growth is a prime means in the development of protein based drugs. Therapeutic monoclonal antibodies are also gaining market in treating inflammatory ailments, cardiovascular diseases and cancer. Media companies and cell reagent producers can have an edge in the cutthroat competition by providing personalized solutions for cell culture requirements of biotech companies. Cell culture forms a vital part of biopharmaceutical product development as it is used in the production of large sophisticated protein molecules, the primary building blocks for biopharmaceuticals. Biopharmaceuticals account for about a quarter of the new drug launches in the global market, thereby also creating a ripple effect and fostering the cell culture market.

Cell/Tissue Culture Supplies market is segmented into two classes – industrial and academic. The industrial sector comprises production and development of biopharmaceuticals, diagnostic, agricultural biotechnology, veterinary products, vaccines and other products. Leading users of cell culture products comprise major pharmaceutical companies, veterinary vaccine manufacturers and diagnostic manufacturers apart from large biotechnology companies. Further, other industries involved in the commercial production of genetically engineered products comprise pharmaceutical, food processing and agricultural industries, genetic and identity testing, cell therapy and tissue engineering involving cell culture media and plant biotechnology.

Regenerative medicine is touted as the next-generation technology to revolutionize the medical system of the future. The basic idea behind regenerative medicine is to cure human ailments by replacing failed body organs and damaged tissues with laboratory-grown cells and organs, akin to replacement of damaged automobile components with brand new spare parts, or promote natural healing properties of the body to repair damaged tissues. Tissue regenerative technologies are gaining growing emphasis with biotechnology companies, thanks to the rapid advancements. The field of regenerative medicine has already innovated products in the tissue engineered cartilage, bladder, and skin. Bioengineered organs that provide therapeutic protein are now the focus of future research. Regenerative medicine involves processes such as multiplication of cells and growing of tissues/organs which are conducted in laboratory settings and the increasing adoption of this stream of medicine is predicted to correspondingly pump up the demand for cell/tissue culture supplies.

Revolutionary 3D cell culture technology has been devised which is intended to help surmount some of the drawbacks associated with 2D cell culture. In-vivo cells have evolved to attain natural 3D structure which is most favorable for their normal development and functioning. Several aspects are transformed subsequent to the process of cell-implantation from living tissues into 2D culture where they are generally housed in 2D monolayers without several of the chemical and physical triggers which underscore their identity and function in-vivo.

As stated by the new market research report on Cell/Tissue Culture Supplies, the US represents the largest market worldwide. However, the Asia-Pacific region offers the highest growth potential owing to increasing research spending in the region. Reagents represents the largest and fastest growing segment, while Sera market is expected to decrease in importance.

Major players in the global marketplace include Affymetrix Inc., AMRESCO Inc., BD Biosciences, Cell Culture Technologies LLC, Cell Essentials Inc., Corning Inc., EMD Millipore, Irvine Scientific Inc., Life Technologies Corporation, Lonza Biologics Plc, MP Biomedicals LLC, ORIGIO a/s, PromoCell GmbH, Sera Laboratories International Ltd., Sigma-Aldrich Corporation, SAFC Biosciences Inc., Thermo Fisher Scientific Inc., and Vitrolife AB.

The research report titled "Cell/Tissue Culture Supplies: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a comprehensive review of market trends, issues, drivers, company profiles, mergers, acquisitions, and other strategic industry activities. The report provides market estimates and projections for Cell/Tissue Culture Supplies (in US$) by Media, Sera, and Reagents segments. Geographic markets analyzed include the United States, Canada, Japan, Europe (France, Germany, Italy, UK, and Rest of Europe), Asia-Pacific, and Latin America.

For more details about this comprehensive market research report, please visit –
http://www.strategyr.com/Cell_Tissue_Culture_Supplies_Market_Report.asp

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world's largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.
Telephone: 408-528-9966
Fax: 408-528-9977
Email: press(at)StrategyR(dot)com
Web Site: http://www.StrategyR.com/

###


Contact

Attachments